Hologic, Inc. (NASDAQ:HOLX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Hologic, Inc. (NASDAQ:HOLX) has been assigned an average rating of “Moderate Buy” from the twelve brokerages that are currently covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $89.91.

HOLX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. raised their price target on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Leerink Partners cut their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Mizuho lowered their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Tuesday, November 5th. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Finally, Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of Hologic in a research note on Tuesday, October 15th.

Hologic Trading Up 0.1 %

NASDAQ HOLX opened at $79.50 on Wednesday. The firm has a market cap of $18.47 billion, a PE ratio of 23.87, a price-to-earnings-growth ratio of 2.51 and a beta of 0.98. Hologic has a 1-year low of $67.59 and a 1-year high of $84.67. The stock has a 50-day moving average of $80.18 and a 200-day moving average of $78.47. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The firm had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same quarter in the previous year, the company posted $0.89 earnings per share. The business’s revenue was up 4.5% on a year-over-year basis. As a group, sell-side analysts forecast that Hologic will post 4.28 EPS for the current year.

Institutional Investors Weigh In On Hologic

Several hedge funds have recently made changes to their positions in the company. Innealta Capital LLC purchased a new position in Hologic during the second quarter valued at $25,000. Wolff Wiese Magana LLC bought a new position in shares of Hologic in the 3rd quarter worth about $25,000. Groupama Asset Managment increased its stake in shares of Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 2,999 shares in the last quarter. iA Global Asset Management Inc. purchased a new position in Hologic during the 1st quarter valued at about $37,000. Finally, Sunbelt Securities Inc. bought a new stake in Hologic during the second quarter worth about $37,000. 94.73% of the stock is currently owned by institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.